The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
This Breakthrough Therapy Designation highlights the impressive clinical benefit of Enhertu over the current standard of care
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
Subscribe To Our Newsletter & Stay Updated
